Clinical Trial

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-05
notable Primary completion pushed: 2029-05-01 -> 2029-06-01 2026-06-05
minor Completion pushed: 2029-09-01 -> 2029-10-01 2026-06-05
Trial Details
NCT Number NCT07581704
Lead Sponsor Christopher Strouse
Conditions Multiple Myeloma
Enrollment 10 participants
Start Date 2026-06-01
Primary Completion 2029-06-01 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-04